Fidelity Investments’s Ginkgo Bioworks DNA Stock Holding History
Bought
Maintained
Sold
Other funds holding DNA
EAM
ACG
JMFC
Fidelity Investments's DNA Position: Q2 2026 in Review
Fidelity Investments increased its Ginkgo Bioworks (DNA) stake by 245% in Q2 2026, buying an estimated $41.3K and bringing the position to 6,951 shares worth $68.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4169.
Fidelity Investments first reported a position in DNA in Q1 2022 and has held it in 18 quarters since. The position peaked at $5M in Q3 2022. 183 funds tracked by Wall St. Rank hold DNA as of Q2 2026.
- Fidelity Investments held 6,951 shares of Ginkgo Bioworks worth $68.9K as of Q2 2026.
- Fidelity Investments bought 4,939 Ginkgo Bioworks shares in Q2 2026, an estimated $41.3K.
- Ginkgo Bioworks made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #4169 holding.
- Fidelity Investments first reported a position in Ginkgo Bioworks in Q1 2022 and has held it in 18 quarters since.
- Fidelity Investments's Ginkgo Bioworks position peaked at $5M in Q3 2022.
- 183 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.
Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.